This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Lysine specific demethylase 1 (LSD1) has been found to have roles that go far beyond its initially discovered function of removing methyl marks from histone tails via an oxidative demethylation mechanism. [1] [2] [3] The clinical potential of this epigenetic eraser in cancer and associated disease areas has been unravelled, largely as a result of experiments exploiting the use of irreversible LSD1 inhibitors developed from tranylcypromine. In a subset of acute myeloid leukaemia (AML), LSD1 has been shown to be important in the maintenance of leukaemia stem cells and the promotion of a block on differentiation. 4 Additionally, LSD1 inhibition has been shown to reactivate the all-trans retinoic acid (ATRA) pathway by increasing the expression of myeloid-differentiation genes, suggesting that a combination of LSD1 inhibitor and ATRA may offer a new therapeutic option for AML subtypes that are generally insensitive to ATRA therapy alone. 5 While tranylcypromine derivatives have facilitated a great deal of research, there is still an unmet need for a variety of reversible tool compounds that display no offtarget pharmacology. GSK-690 (1, Figure 1 ) is a versatile start-point for the development of reversible LSD1 inhibitors, however the development of this compound was hindered by a human ether-a-go-go related gene (hERG) liability. 7 Aromatic scaffold replacements are an attractive and logical way to retain potency while moving into novel intellectual property space. 8 To that end, patents that disclose a number of mono-and bicycle heterocyclic scaffolds that replace the central pyridine ring have recently been disclosed. [9] [10] [11] [12] [13] [14] We instead looked to focus on scaffold-hops that featured ring systems that were partly or fully saturated. We hypothesised that the decreased lipophilicity and increased flexibility of a saturated core structure may be a valid strategy to try and overcome the persistent hERG liability of 1 and related derivatives. [15] [16] An increase in sp 3 character has the effect of increasing the molecules 3-dimensional (3D) shape and reducing the aromatic ring count, which have both been noted as important factors in improving the developability of compounds as potential drugs. [17] [18] On the other hand, this approach brings the added complications of potential stereocenters and synthetic challenges of transformations that would be trivial on an aromatic scaffold but remain complex in the timeframe of hit-to-lead development. 19 Herein, we describe our efforts to identify series of reversible inhibitors with scaffolds containing multiple sp 3 centres, and their elaboration and development into potent inhibitors of LSD1 as confirmed by biochemical, surface plasmon resonance (SPR) and cellular biomarker assays with significantly reduced activity against the hERG ion channel.
To investigate the potential of saturated scaffold-hops from compound 1, we begin by using Cresset Spark (Welwyn Garden City, UK) software to identify potential replacements of the pyridine core incorporating sp 3 centres at the attachment points of the two aryl groups. This identified two potential isosteric replacements that appeared to be synthetically accessible via cycloaddition reactions, namely β-lactams and pyrrolidines. From there, we refined the spatial overlap between the scaffold-hops and 1 using Cresset Torch to design potential ligands ( Figure 1 ). The cis-β-lactam diastereomers (2) were predicted to be far more favourable than the trans-(3), as this allows the two aryl groups be oriented in the same plane as modelled by 1, whereas in the trans-diastereoisomers the aryl groups are forced out of the plane. Modelling potential pyrrolidine scaffolds on the other hand, the increased flexibility of the fully saturated ring system means that it is possible for a trans-diastereoisomer (4) to adopt a conformation where the two hydrogens sit axially, with the aryl rings oriented only slightly out of plane. Hz; trans-J = 2.3 Hz) allowed for identification of the structure of each product. 20 These enantiomeric mixtures were tested for their inhibitory activity against LSD1 in biochemical time resolved fluorescent resonance energy transfer (TR-FRET) and biophysical surface plasmon resonance (SPR) assays, as previously reported. 16 While the trans-diastereoisomers (8-10) were inactive in both assay formats (IC 50 > 30µM and K d > 100 µM), we were encouraged to find that the cis-diastereoisomers, which were predicted to adopt a more favourable conformation to act as an isostere of 1, did show modest activity and reversibility against LSD1 by SPR (8 K d = 38 µM, 10 K d = 53 µM). Historically 3,4-disubstituted pyrrolidines have been constructed by the reaction of alkenes most commonly with azomethine ylide sources such as N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine in the presence of trifluoroacetic acid. 21 However, we found this combination of reagents was unable to effect conversion of the stilbene precursors to the cycloaddition product. The trans-pyrrolidines were synthesised via 1,3-dipolar cycloaddition of trans-stilbene precursors with trimethylamine oxide in the presence of excess LDA, as developed by Davoren and coworkers. 22 This afforded the N-methyl products, which were deprotected by reaction with 1-chloroethyl chloroformate followed by refluxing in methanol. Amide coupling, followed by Boc-deprotection, afforded amines 21a-h, 22a-b and 22a-e.
Pyrrolidines 21a-h were screened against LSD1 by biochemical TR-FRET assay, and we were gratified to observe that this series transferred the spatial and electrostatic similarity to 1 into promising levels of potency ( Table 1) . Optimisation of the basic centre focussed upon varying the length and flexibility of the linker between the amide and the amine functionalities. Piperidine 21a and trans-cyclohexylamine 21b
showed reasonable levels of activity, with sub-micromolar K d values. From initial results, introduction of a methylene unit between the amide and the cyclohexane looked to offer improved affinity (21c-f).
Moving the methylene linker from the amide to the amine led to transexamic acid derivative 21g which displayed low nanomolar activity by both SPR and biochemical assay, and was only ~2-fold less active than 1. Methylation of this amine (21h) was poorly tolerated, resulting in a ~4-fold drop-off in potency
The patent literature generally deviates away from the p-tolyl group, and we were keen to explore replacements that are frequently observed, to see if this would offer an additional route to improve potency ( Table 2 ). The methoxypyridine replacement (23a-b) showed a disappointing 8-15-fold drop-off in potency in comparison to matched pairs 21d and 21f. More successful was replacement with a methylindazole (23a-e), however potency could not be improved further. The matched pair of 21g (23d) showed only a ~2-fold drop off by SPR. Interestingly, replacing the cyclohexyl motif of 23d with an aromatic system (23c) shows a ~20-fold decrease in potency, suggesting the importance of a saturated system in this region. experiments. Geometric mean of at least two independent experimental determinations given. experiments. Geometric mean of at least two independent experimental determinations given.
Using knowledge of the binding mode of 1 bound to LSD1, 7 we used Glide (Schrödinger, New York, USA), 24 to model both enantiomers of 21g into the crystal structure of LSD1 bound to the reversible ligand tetrahydrofolate (PDB: 4KUM). 25 There was no significant difference between the docking scores of each enantiomer, however we are yet to separate the enantiomers and test this experimentally. The predicted binding mode of (3R,4R)-21g is given in Figure 2 . The compound was predicted to made two key hydrogen bonding interactions. The nitrile forms a hydrogen bond with Lys661, with the basic centre being directed towards Asp555 and Asp556. Targeting these acidic residues appears to be a valuable strategy and has been seen with other structurally distinct series of reversible inhibitors. [26] [27] The widevariety of scaffold hops from 1 appears to be due to the lack of close contacts between the core (in this case the pyrrolidine ring) and the protein. Thus, this central portion of the molecule could be used as a versatile handle to improve DMPK. The p-tolyl groups points into a hydrophobic channel formed by Ile356, Leu677, Leu693, and Trp695. Compound 21g demonstrated excellent selectivity over both MAO-A and MAO-B (IC 50 > 25 µM), and improved selectivity over the hERG ion channel compared to 1 (21g IC 50 = 12.1 µM, 1 IC 50 = 3.2 µM). 28 The increase in expression levels of the cell surface marker CD86 in THP-1 acute myeloid leukaemia cells as a response to LSD1 inhibition has been used to provide a robust cellular assay format (Figure 3 ). 27 We tested our most active derivative, 21g, alongside 1, and a previously described hydroxypyrazole based inhibitor of LSD1 (24) . 16 All three compounds induced the expression of CD86 after 48 h in a dose dependent manner, as expected, although 21g displayed marginally less activity than 1.
In summary, we have designed a series of 4-(pyrrolidin-3-yl)benzonitrile derivatives that demonstrate potent activity against LSD1 in biochemical assays and by SPR. The most potent derivative, 21g, demonstrates comparable levels of cellular activity to other previously described reversible inhibitors of LSD1, complete selectivity against related monoamine oxidase enzymes and shows improved selectivity in comparison to 1 against the hERG ion channel. This profile makes 21g a useful cell-active tool compound to further explore the role of LSD1 in cells. This series represents the first example of a potent saturated scaffold-hop from 1, and is an excellent start-point for further optimisation. 
